Subscribe Now Subscribe Today
Research Article

HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast

Mutiu A. Alabi, Olugbenga O. Adebawo, Oluwole A. Daini, Stella B. Somiari and Richard I. Somiari
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Background and Objectives: The initiating steps and precise pathway of breast tumorigenesis are poorly understood and it is unclear if Ductal Carcinoma In Situ (DCIS) progresses to invasive ductal carcinoma (IDCA) of the breast. This study was undertaken to identify proteins that are differentially expressed between IDCA and DCIS and that may predict the invasive potential of breast tumors. Methodology: It is utilized that the two-dimensional difference in gel electrophoresis technology (2D-DIGE) and tandem mass spectrometry (LC-MS/MS) to perform proteomic analysis of IDCA (MCF-7 and BT-474) and DCIS (HCC-1500 and HCC-38) cell lines. Results: Identified 10 proteins that were differentially expressed between IDCA and DCIS (≥2-fold difference; p≤0.05) and classified the proteins according to their Gene Ontology (GO). Out of these proteins, 60 kDa mitochondrial heat shock protein (HSPD1), Heat Shock Protein Beta 1 (HSPB1) and the voltage-dependent anion-selective channel protein 1 (VDAC1) are over expressed in IDCA compared to DCIS. Conclusion: The functional role of the differentially expressed proteins suggests that they may serve as biomarkers for identification of tumors with invasive potential.

Related Articles in ASCI
Search in Google Scholar
View Citation
Report Citation

  How to cite this article:

Mutiu A. Alabi, Olugbenga O. Adebawo, Oluwole A. Daini, Stella B. Somiari and Richard I. Somiari, 2016. HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast. International Journal of Cancer Research, 12: 82-91.

DOI: 10.3923/ijcr.2016.82.91

Received: December 04, 2015; Accepted: February 19, 2016; Published: March 15, 2016


Breast cancer is the most commonly diagnosed cancer in women and it accounts for a significant number of cancer–related deaths in women in Nigeria1,2. According to the American Cancer Society3, breast cancer ranks second as the cause of cancer death in women in America. It was estimated that 234,190 new breast cancer cases will be diagnosed in the US in 2015 and about 40,730 were expected to die from the disease3.

There are different types of breast cancer. Cancer cells that remain confined to the lobule and the ducts are called in situ or non-invasive. They are sometimes also referred to as pre-cancers in recognition of the fact that these cells have not yet gained the ability to spread to other parts of the body, which is the feature that most people associate with cancer. The non-invasive breast cancers are ductal carcinoma in situ also called intraductal carcinoma and lobular carcinoma in situ and accounts for about 10% of all cases4.

An invasive cancer is one, where the cells have moved outside the ducts and lobules into the surrounding breast tissue. Infiltrating ductal carcinoma, an invasive cancer, penetrates the wall of a duct and is the most common form of breast cancer constituting about 70% of all cases. Infiltrating lobular carcinoma, also an invasive cancer spreads through the wall of the lobule. It accounts for about 8% of all breast cancer cases. The breast can be divided into 4 quadrants excluding the nipple and cancer is most frequent in the upper outer quadrant of the breast. Each quadrant has its rate and percentage of occurrence4.

Ductal carcinoma in situ lies along a broad range of related qualities of preinvasive lesions originating within normal breast tissue with histologic progression from atypical hyperplasia to invasive breast cancer5. Although, the initiating steps and precise pathways of breast tumorigenesis remain poorly defined, it appears that nearly all invasive breast cancers arise from in situ carcinomas. Hence, this study was undertaken to use proteomics to identify proteins that are differentially expressed in invasive ductal carcinoma (IDCA) when compared with Ductal Carcinoma In Situ (DCIS). Differentially expressed proteins may serve as biomarkers differentiating IDCA from DCIS and most importantly find utility in predicting the onset of invasion of breast cancer.


Human breast cancer cell lines: Four human breast cancer cell lines namely MCF-7, HCC-38, HCC-1500 and BT-474 were obtained from American Type Cultural Collection (ATCC), Manassas, VA, USA and used for the study. The cell lines were cultured and maintained at 37.0°C in the presence of 95% atmospheric air and 5% carbon dioxide (CO2) using a complete growth medium (MCF-7 in ATCC-formulated Eagle’s Minimum Essential Medium, Catalog No. 30-2003, BT-474 in ATCC Hybri-Care Medium; Catalog No. 46-× and HCC-38 and HCC-1500 in ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001) supplemented with fetal bovine serum. All tissue culture experiments were performed at the Windber Research Institute, Windber, PA, USA. At the end of cell culture, the cells were harvested and re-suspended in ToPI-DIGE buffer (ITSI-Biosciences Johnstown, PA, USA) and stored at -80°C until analyzed.

Two-dimensional difference gel electrophoresis (2D-DIGE): The samples were analyzed by 2D-DIGE and tandem mass spectrometry. Briefly, total protein was isolated from each cell line using the ToPI-DIGE kit, total protein concentration determined using the ToPA protein assay6. For 2D-DIGE, the minimal-labeling protocol previously described7 was used to label 50 μg of total protein from each sample using 200 pmole of Cy3 or Cy5 fluorescent dyes. Additionally, an equal aliquot of protein from all samples in the study were pooled and labeled with Cy2 dye. The Cy2 labeled pooled sample was added to each gel and used as the universal internal control (U) to allow for the quantitative comparison of all samples. The Cy2, Cy3 and Cy5 labeled samples in addition to 175 μg of unlabelled protein were mixed and loaded on a single 24 cm IEF strip, pH 3-10 NL for the 1st dimension separation using the Ettan IPGphor II (GE Healthcare, Piscataway, NJ). The strips were rehydrated in the presence of the samples for 12 h at 30 V and then focused for a total of 65,000 V h6. For 2nd dimension separation, each focused strip was loaded onto a 24×20 cm, 12.5% SDS-PAGE gel and run for 4 h. After 2D-DIGE (1st and 2nd dimension separations) the gels were scanned at three wavelengths with a DIGE enabled variable mode digital scanner (Typhoon Trio; GE Healthcare Piscataway, NJ) to capture the Cy3, Cy5 and Cy2 signals. Subsequently, each gel was stained with Sypro Ruby, scanned and a pick list of candidate proteins generated as previously described6.

Image analysis: The captured gel images were analyzed using the difference in gel analysis (DIA) module of DeCyder software (version 6.0; GE Healthcare Lifesciences, Piscataway, NJ, USA).

The normalized spot volumes generated in DeCyder that showed ≥2-fold difference in abundance between the IDCA and DCIS cell lines (p≤0.05) were considered candidate differentially expressed proteins. After DIA, each gel was stained with Sypro Ruby to allow accurate identification and matching of spots to be picked7.

Candidate protein spot processing: Candidate protein spots were picked using the Ettan robotic spot picker (GE Healthcare Lifesciences, Piscataway, NJ, USA) and in-gel digested using the Ettan robotic spot digester. Briefly, the spots were picked into 96-well plates and digested with trypsin overnight (15-16 h) at room temperature. The digested samples were extracted in 50 μL of 50% acetonitrile/0.1% formic acid prior to mass spectrometry6.

Protein identification by mass spectrometry: Protein identification was performed using a thermo scientific surveyor High-Performance Liquid Chromatography (HPLC) system connected to an LCQ DECA XP plus iontrap mass spectrometer with a nanospray ionization source (ThermoFinnigan, San Jose, CA). Mass spectrometry conditions were as previously described6.

Database search: Each acquired MS/MS spectrum was searched against the international protein index database (human) version 3.72 using the SEQUEST search algorithm. Proteins were identified when two or more unique peptides had X-correlation scores above 1.5, 2.0 and 2.5 for respective charge states of +1, +2 and +3 and the delta CN score was greater than 0.1. Each candidate ID derived from the above search was then manually examined in the SwissProt database to eliminate redundancy of synonymous proteins. A protein’s name and accession number were reported based on SwissProt except for proteins that are only deposited in the NCBI database.

Gene ontology: Differentially expressed proteins identified by 2D-DIGE were further classified according to their Gene Ontology (GO) using NCBI and KEGGS databases8. The GO provides a controlled vocabulary to describe proteins in terms of Molecular Function (MF), Cellular Component (CC) and Biological Process (BP).

Statistical analysis: The t-test was used to determine the statistical significance of the difference in protein expression in IDCA compared with DCIS. For all comparisons, the level of significance was set at p≤0.05.


Average protein concentrations: The average protein concentrations of the cell lines (MCF-7, HCC-38, HCC-1500 and BT-474) were as presented in Table 1. The BT-474 cell line had the highest protein concentration (53,000 μg mL–1) while HCC-38 cell line had the lowest protein concentration (7,360 μg mL–1).

Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast
Fig. 1: 2D-DIGE gel image showing candidate protein spots from MCF-7 (Green) vs: HCC-38 (Red) cells

Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast
Fig. 2: 2D-DIGE gel image showing candidate protein spots from HCC-1500 (Green) vs: BT-474 (Red)

Table 1: Average protein concentrations of the cell lines
Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast

Identifying proteins differentially expressed in breast tumor cell lines: The DeCyder software was used to analyze the 2D-DIGE gel images using the difference in gel analysis workspace. A total of 18 candidate protein spots were identified as differentially expressed between HCC-38 vs. MCF-7 (Fig. 1) and between HCC-1500 vs. BT-474 (Fig. 2) by a factor of at least 2-fold (Table 2).

Table 2: Average ratio of protein expression between MCF-7 vs. HCC-38 and BT-474 vs. HCC-1500 cell lines
Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast

Protein identification by mass spectrometry: The selected protein spots were excised, in-gel digested with trypsin and analyzed by LC-MS/MS. The raw data files were used to search against the Swiss-Prot human database using Mascot as a primary database search algorithm. Expasy Aldente was used as a complementary algorithm for additional confirmation to reduce the possibility of false positive identification. Agreement between the apparent MW and pI observed on the 2D-DIGE gel and the theoretical values of the identified proteins provided additional support for positive identification. Eleven proteins of interest were identified in the HCC-38 vs. MCF-7 comparison (Fig. 3) and 13 were identified in the HCC-1500 vs. BT-474 comparison. Out of these, 10 proteins showed statistically significant difference in spot volume (≥2-fold) between the DCIS and IDCA cell lines (Table 3). Three proteins out of the 10 proteins showed over expression in IDCA cell lines when compared with DCIS cell lines. Some of the identified proteins may exist in multiple forms, as they were identified in spots picked from different sections of the gel (Table 4 and Fig. 4). It is unclear as to whether these proteins exist in multiple forms due to biological differences or processing influences, such as carbamylation, a common modification when using urea buffer, which causes shifts in the isoelectric point of the protein.

Gene ontology classification: The proteins of interest were categorized using NCBI and KEGGS databases to determine their molecular function, cellular component and biological process (Table 4). The most significant pathway associated with the differentially expressed proteins identified was the apoptosis signaling pathway.


Proteomics is increasingly being used to identify proteins that show differential expression in cancer9. Such protein alterations may eventually contribute to increasing this understanding of cancer pathogenesis as well as aid in the development of effective strategies for cancer diagnosis and treatment.

The proteins identified in this study span a wide range of functions and if validated may have value as diagnostic and prognostic biomarkers for breast cancer. Among the proteins identified were 60 kDa heat shock protein, mitochondrial (HSPD1), Heat Shock Protein Beta-1 (HSPB1) and voltage-dependent anion-selective channel protein 1 (VDAC1), which showed increased expression in IDCA cell line when compared with DCIS cell line.

The proteomic analysis revealed that the expression of 60 kDa HSPD1 was increased in IDCA cell lines (Table 2 and 4). The observation that HSPD1 is over expressed in IDCA is of interest and deserves further studies to determine if the overexpression is a result of the induction or inhibition of genes and/or degeneration or modification of proteins during carcinogenesis.

The HSPD1 is constitutively expressed under normal conditions and its expression is induced by stressful conditions such as heat shock, mitochondrial damage and mtDNA depletion10-14. The overexpression of HSPD1 in IDCA breast cancer cell lines suggests that this protein might play a different role in breast carcinogenesis15,16. Paepe15 and Cappello et al.17 reported that elevated expression of HSPD1 may have a protective role against cancer development (i.e., the blockade of apoptotic machinery that usually takes place during cancer progression).

Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast
Fig. 3: Representative simulated 3D images of candidate protein spots differentially expressed between MCF-7 (Cy3) and HCC-38 (Cy5)

Table 3: List of proteins differentially expressed between IDCA and DCIS
Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast
*Sequence coverage (%) and No. of peptides identified with #1%, PI: Protease inhibitor and MW: Molecular weight

Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast
Fig. 4: Location of 14 differentially expressed proteins identified by mass spectrometry

Table 4: Expression pattern and gene ontology of differentially expressed protein in IDCA/DCIS cell lines
Image for - HSPD1, HSPB1 and VDAC1 are Over-expressed in Invasive Ductal Carcinoma of the Breast
↑: Overexpressed and↓ : Underexpressed

The involvement of HSPD1 in the process of apoptosis and tumorigenesis is still in dispute12,15,16. An antiapoptotic effect of HSPD1 and down-regulation of HSPD1 have been reported in cardiac myocytes and bronchial cancer17. On the other hand, overexpression of HSPD1 has been reported in prostate and ovarian carcinomas and myeloid leukemia15,17,18. Moreover, recent studies showed upregulation of HSPD1 during carcinogenesis of the large bowel and the uterine exocervix15,17,18.

The results of the study work revealed overexpression of Heat Shock Protein Beta-1 (HSPB1) in IDCA breast cancer cell lines. The HSPB1 belongs to the family of small stress proteins that are constitutively abundant and ubiquitously present in cells12,14,15. The HSPB1 regulates apoptosis through its ability to interact with key components of the apoptotic-signaling pathways15,16. Changes in the intracellular redox balance and production of reactive oxygen species initiate the apoptotic cascade through changes in the mitochondria and release of pro-apoptotic factors14,15. The HSPB1 can maintain both the redox homeostasis and mitochondrial stability in the cell14.

The HSPB1 helps protect cells under adverse conditions such as infection, inflammation, exposure to toxins, elevated temperature, injury and disease10. Heat shock proteins block signals that lead to programmed cell death or apoptosis10,14. Up-regulated expression of HSPB1 has been reported in several cancers such as ovarian cancer, renal cancer, various leukemias, bladder cancer, etc.19-22. The overexpression of HSPs in tumorous tissues has been implicated to have prognostic value in patients with ovarian, renal and bladder cancer15,20,23,24.

Recently, there have been reports that high HSPB1 expression levels are associated with a poor prognosis for specific cancers including gastric, liver and prostate carcinomas and osteosarcomas10,12,14,15. Furthermore, expression of HSPB1 in primary breast cancers is associated with a short survival for node-negative patients and increased HSPB1 expression levels have been found in highly metastatic variant breast cancer cells10,15,23,25. However, osteolytic bone metastases of human breast cancer cells are reduced by HSPB1 overexpression26. It is suggested that overexpression of HSPB1 may render tumors more resistant to some commonly used chemotherapeutic agents that induce apoptosis27.

The HSPB1 is highly expressed in Her2-positive tumors10,28. The HSPB1 is one of the downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and is a modulator of Stat3-regulated apoptosis29,30. The Ser78 phosphorylation of HSPB1 is mainly regulated by the Her2-p38 MAPK pathway and is significantly correlated with Her2 and lymph-node positivity10,28.

Overexpression of Voltage Dependent Anion-selective Channel (VDAC1) was observed in the IDCA breast cancer cell lines studied. Shoshan-Barmatz and Mizrachi31, Zhang et al.28 and Shinohara et al.32 have also reported the overexpression of VDAC1 in IDCA. The overexpression of VDAC1 could be linked to a number of apoptotic stimuli in the IDCA cell lines. The VDAC is located in the mitochondrial outer membrane, functions as gatekeeper for the entry and exit of mitochondrial metabolites and thus controls cross-talk between mitochondria and the cytosol31,33.

The VDAC also serves as a site for the docking of cytosolic proteins, such as hexokinase and is recognized as a key protein in mitochondria-mediated apoptosis31,32. The role of VDAC in apoptosis has emerged from various studies showing its involvement in cytochrome C release and apoptotic cell death as well as its interaction with proteins regulating apoptosis, including the mitochondria-bound isoforms of hexokinase HK-I and HK-II31,32.

The role of VDAC1 in regulating apoptosis has been the subject of considerable debate31. Knockout of all three isoforms of VDAC was shown to have no effect on mitochondrial apoptosis in mouse embryonic fibrosis31,34, whereas conflicting data has indicated that the N-terminal of VDAC1 is essential for release of cytochrome C following various apoptotic stimuli31,35. The VDAC1 promotes aerobic glycolysis in cell lines through its interaction with hexokinase at the outer mitochondrial membrane31,36,37.

Other studies have shown that hexokinase binds to mitochondria via the N-term of VDAC1 and that this is associated with resistance to mitochondrial apoptosis31,35,38. These reported interactions between VDAC1 and hexokinase imply a pro-survival rather than pro-apoptotic role for VDAC1 activity in cancerous cells.

Thus, VDAC may act as a Mitochondrial Permeability Transition Pore (MPTP) on the outer mitochondrial membrane. It was reported that O2 but not H2O2 induces a rapid and massive release of cytochrome C from mitochondria, which is a central event in apoptosis31,39,40. Reduced cytotoxicity of FNQ13 in VDAC knockdown cells might be due to lower cytochrome C release and therefore, reduced induction of apoptosis31,41.

On the other hand, VDAC1 in the plasma membrane has recently been shown to possess NADH-ferricyanide reductase activity, which could directly catalyze the reduction of ferricyanide in the presence of NADH31,39. Simamura et al.41 showed that FNQs induces the NADH-dependent production of ROS on the mitochondrial outer membrane and proposes that VDAC has a similar function as NAD(P)H-quinone oxidoreducase 1 and therefore, mitochondrial VDAC may catalyze the reduction of anticancer drugs such as furanonaphthoquinones and leading to mitochondrial production of ROS. However, NAD(P)H-quinone oxidoreductase 1, which activates mitomycin C is localized in the cytosol but not on the mitochondrial outer membrane and mediates the two-electron reduction of substrates, suggesting that VDAC and NAD(P)H quinone oxidoreductase1 have different functions31,42.


The combination of 2D-DIGE and nano-LC-MS/MS technologies enabled the identification of proteins differentially expressed between invasive ductal carcinoma (IDCA) and Ductal Carcinoma In Situ (DCIS) breast cancer cell lines. The expression levels of 60 kDa mitochondrial heat shock protein (HSPD1), Voltage Dependent Anion-selective Channel protein 1 (VDAC1) and Heat Shock Protein Beta 1 (HSPB1) were higher in IDCA. However, no far reaching conclusions can be made from the data obtained since cell lines were used in the study. Nevertheless, we were encouraged because other studies have identified differential expression of similar proteins in cancer. It is expected that this study will stimulate further studies utilizing tumor biopsies to determine if the 60 kDa HSPD1, VDAC1 and HSPB1 are also differentially expressed in clinical specimens. If independently validated using tumor biopsies, then HSPD1, VDAC1 and HSPB1 may represent a new set of biomarkers that can be used to predict the invasive potential of breast tumors.


The authors wish to thank the Tertiary Education Trust Fund (TETF), Nigeria for their financial support of the study. The authors are grateful to Stephen Russell, Florentina Mayko and Steve Wolve of ITSI Biosciences LLC, Jownstown, PA, USA for their technical support. The cell lines used for the study were provided by George Iida, PhD, Windber Research Institute, Windber, PA, USA.


1:  Alabi, M.A., 2014. Proteins expression in pre-invasive and invasive breast carcinoma. Ph.D. Thesis, Biochemistry Department, Olabisi Onabanjo University, Ago-Iwoye, Nigeria.

2:  Jedy-Agba, E.E., M.P. Curado, E. Oga, M.O. Samaila and E.R. Ezeome et al., 2012. The role of hospital-based cancer registries in low and middle income countries-The Nigerian case study. Cancer Epiemiol., 36: 430-435.
CrossRef  |  Direct Link  |  

3:  ACS., 2015. Cancer facts and figures 2015. American Cancer Society, Atlanta, GA., USA., pp: 1-156.

4:  Michaelson, J., S. Satija, R. Moore, G. Weber, E. Halpern, A. Garland and D.B. Kopans, 2001. Observations on invasive breast cancer diagnosed in a service screening and diagnostic breast imaging program. J. Women's Imaging, 3: 99-104.
Direct Link  |  

5:  Burstein, H.J., J.R. Harris and M. Morrow, 2008. Malignant Tumors of the Breast. In: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, DeVita, V.T., T.S. Lawrence and S.A. Rosenberg (Eds.). Lippincott Williams and Wilkins, Philadelphia PA., USA., ISBN-13: 9780781772075, pp: 1606-1654

6:  Boyiri, T., R.I. Somiari, S. Russell, C. Aliaga and K. El-Bayoumy, 2009. Proteomics of rat prostate lobes treated with 2-N-hydroxylamino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 5α-dihydrotestosterone, individually and in combination. Int. J. Oncol., 35: 559-567.
CrossRef  |  Direct Link  |  

7:  Somiari, R.I., A. Sullivan, S. Russell, S. Somiari and H. Hu et al., 2003. High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics, 3: 1863-1873.
CrossRef  |  Direct Link  |  

8:  Arciero, C., S.B. Somiari, C.D. Shriver, H. Brzeski and R. Jordan et al., 2003. Functional relationship and gene ontology classification of breast cancer biomarkers. Int. J. Biol. Markers, 18: 241-272.
PubMed  |  Direct Link  |  

9:  Somiari, R.I., S. Somiari, S. Russell and C.D. Shriver, 2005. Proteomics of breast carcinoma. J. Chromatogr. B, 815: 215-225.
CrossRef  |  Direct Link  |  

10:  Kim, L.S. and J.H. Kim, 2011. Heat shock protein as molecular targets for breast cancer therapeutics. J. Breast Cancer, 14: 167-174.
CrossRef  |  Direct Link  |  

11:  Santagata, S., R. Hu, N.U. Lin, M.L. Mendillo and L.C. Collins et al., 2011. High levels of nuclear Heat-Shock Factor 1 (HSF1) are associated with poor prognosis in breast cancer. Proc. Natl. Acad. Sci. USA., 108: 18378-18383.
CrossRef  |  Direct Link  |  

12:  Gibert, B., B. Eckel, L. Fasquelle, M. Moulin and F. Bouhallier et al., 2012. Knock down of heat shock protein 27 (HspB1) induces degradation of several putative client proteins. PLoS One, Vol. 7.
CrossRef  |  Direct Link  |  

13:  Sims, J.D., J. McCready and D.G. Jay, 2012. Extracellular Heat Shock Protein (Hsp)70 and Hsp90α assist in matrix metalloproteinase-2 activation and breast cancer cell migration and invasion. PLoS One, Vol. 64.
CrossRef  |  Direct Link  |  

14:  Ciocca, D.R. and S.K. Calderwood, 2005. Heat shock proteins in cancer: Diagnostic, prognostic, predictive and treatment implications. Cell Stress Chaperones, 10: 86-103.
PubMed  |  Direct Link  |  

15:  Paepe, B.D., 2012. Mitochondrial markers for cancer: Relevance to diagnosis, therapy and prognosis and general understanding of malignant disease mechanisms. ISRN Pathol.
CrossRef  |  

16:  Romanucci, M., T. Bastow and L.D. Salda, 2008. Heat shock proteins in animal neoplasms and human tumours-a comparison. Cell Stress Chaperones, 133: 253-262.
CrossRef  |  Direct Link  |  

17:  Cappello, F., E.C. de Macario, L. Marasa, G. Zummo and A.J.L. Macario, 2008. Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy. Cancer Biol. Ther., 7: 801-809.
CrossRef  |  Direct Link  |  

18:  Cappello, F., M. Bellafiore, A. Palma, S. David and V. Marciano et al., 2003. 60KDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis. Eur. J. Histochem., 47: 105-110.
PubMed  |  Direct Link  |  

19:  Kang, Y., W. He, S. Tulley, G.P. Gupta and I. Serganova et al., 2005. Breast cancer bone metastasis mediated by the smad tumor suppressor pathway. Proc. Natl. Acad. Sci. USA., 102: 13909-13914.
CrossRef  |  Direct Link  |  

20:  Lebret, T., R.W.G. Watson, V. Molinie, A. O'Neill, C. Gabriel, J.M. Fitzpatrick and H. Botto, 2003. Heat shock proteins HSP27, HSP60, HSP70 and HSP90: Expression in bladder carcinoma. Cancer, 98: 970-977.
CrossRef  |  Direct Link  |  

21:  Jaattela, M., 2002. Programmed cell death: Many ways for cells to die decently. Ann. Med., 346: 480-488.
CrossRef  |  Direct Link  |  

22:  Jolly, C. and R.I. Morimoto, 2000. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst., 92: 1564-1572.
CrossRef  |  Direct Link  |  

23:  Thanner, F., M.W. Sutterlin, M. Kapp, L. Rieger and A.K. Morr et al., 2005. Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Res., 25: 1649-1653.
PubMed  |  Direct Link  |  

24:  Mosser, D.D. and R.I. Morimoto, 2004. Molecular chaperones and the stress of oncogenesis. Oncogene, 23: 2907-2918.
CrossRef  |  Direct Link  |  

25:  Li, D.Q., L. Wang, F. Fei, Y.F. Hou and J.M. Luo et al., 2006. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics, 6: 3352-3368.
CrossRef  |  Direct Link  |  

26:  Lemieux, P., S. Oesterreich, J.A. Lawrence, P.S. Steeg, S.G. Hilsenbeck, J.M. Harvey and S.A. Fuqua, 1997. The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis, 17: 113-123.
PubMed  |  Direct Link  |  

27:  Cayado-Gutierrez, N., V.L. Moncalero, E.M. Rosales, W. Beron and E.E. Salvatierra et al., 2013. Downregulation of Hsp27 (HSPB1) in MCF-7 human breast cancer cells induces upregulation of PTEN. Cell Stress Chaperones, 18: 234-249.
CrossRef  |  Direct Link  |  

28:  Zhang, Y. and X. Shen, 2007. Heat shock protein 27 protects L929 cells from cisplatin-induced apoptosis by enhancing Akt activation and abating suppression of thioredoxin reductase activity. Clin. Cancer Res., 13: 2855-2864.
CrossRef  |  Direct Link  |  

29:  Rocchi, P., E. Beraldi, S. Ettinger, L. Fazli, R.L. Vessella, C. Nelson and M. Gleave, 2005. Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res., 65: 11083-11093.
CrossRef  |  Direct Link  |  

30:  Xu, J., L. Liao, G. Ning, H. Yoshida-Komiya, C. Deng and B.W. O'Malley, 2000. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function and mammary gland development. Proc. Natl. Acad. Sci. USA., 97: 6379-6384.
CrossRef  |  Direct Link  |  

31:  Shoshan-Barmatz, V. and D. Mizrachi, 2012. VDAC1: From structure to cancer therapy. Mol. Cell. Oncol., Vol. 2.
CrossRef  |  Direct Link  |  

32:  Shinohara, Y., T. Ishida, M. Hino, N. Yamazaki, Y. Baba and H. Terada, 2000. Characterization of porin isoforms expressed in tumor cells. Eur. J. Biochem., 267: 6067-6073.
CrossRef  |  PubMed  |  Direct Link  |  

33:  Chacko, A.D., F. Liberante, I. Paul, D.B. Longley and D.A. Fennell, 2010. Voltage dependent anion channel-1 regulates death receptor mediated apoptosis by enabling cleavage of caspase-8. BMC Cancer, Vol. 10.
CrossRef  |  Direct Link  |  

34:  Baines, C.P., R.A. Kaiser, T. Sheiko, W.J. Craigen and J.D. Molkentin, 2007. Voltage-dependent anion channels are dispensable for mitochondrial-dependent cell death. Nat. Cell Biol., 9: 550-555.
CrossRef  |  Direct Link  |  

35:  Abu-Hamad, S., N. Arbel, D. Calo, L. Arzoine and A. Israelson et al., 2009. The VDAC1 N-terminus is essential both for apoptosis and the protective effect of anti-apoptotic proteins. J. Cell Sci., 122: 1906-1916.
CrossRef  |  Direct Link  |  

36:  Majewski, N., V. Nogueira, P. Bhaskar, P.E. Coy and J.E. Skeen et al., 2004. Hexokinase-mitochondria interaction mediated by akt is required to inhibit apoptosis in the presence or absence of bax and bak. Mol. Cell, 16: 819-830.
CrossRef  |  Direct Link  |  

37:  Pedersen, P.L., 2008. Voltage Dependent Anion Channels (VDACs): A brief introduction with a focus on the outer mitochondrial compartment's roles together with hexokinase-2 in the Warburg effect in cancer. J. Bioenergetics Biomembr., 40: 123-126.
CrossRef  |  Direct Link  |  

38:  Pastorino, J.G., N. Shulga and J.B. Hoek, 2002. Mitochondrial binding of hexokinase II inhibits bax-induced cytochrome c release and apoptosis. J. Biol. Chem., 277: 7610-7618.
CrossRef  |  Direct Link  |  

39:  Baker, M.A., D.J.R. Lane, J.D. Ly, D. de Pinto and A. Lawen, 2004. VDAC1 is a transplasma membrane NADH-ferricyanide reductase. J. Biol. Chem., 279: 4811-4819.
CrossRef  |  PubMed  |  Direct Link  |  

40:  Madesh, M. and G. Hajnoczky, 2001. VDAC-dependent permeabilization of the outer mitochondrial membrane by superoxide induces rapid and massive cytochrome c release. J. Cell Biol., 155: 1003-1016.
CrossRef  |  Direct Link  |  

41:  Simamura, E., K.I. Hirai, H. Shimada, J. Koyama, Y. Niwa and S. Shimizu, 2006. Furanonaphthoquinones cause apoptosis of cancer cells by inducing the production of reactive oxygen species by the mitochondrial voltage-dependent anion channel. Cancer Biol. Ther., 5: 1523-1529.
CrossRef  |  Direct Link  |  

42:  Okada, S.F., W.K. O'Neal, P. Huang, R.A. Nicholas and L.E. Ostrowski et al., 2004. Voltage-Dependent Anion Channel-1 (VDAC-1) contributes to ATP release and cell volume regulation in murine cells. J. Gen. Physiol., 124: 513-526.
CrossRef  |  Direct Link  |  

©  2022 Science Alert. All Rights Reserved